Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-11 8:32 pm Purchase |
2025-04-04 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management, LLC | 5,390,964 13.290% |
5,390,964 (New Position) |
Filing History |
| 2025-02-14 9:10 pm Purchase |
2024-12-31 | 13G | iBio, Inc. IBIO |
ADAR1 Capital Management, LLC | 1,095,967 9.990% |
129,669 (+13.42%) |
Filing History |
| 2025-02-14 9:05 pm Sale |
2024-12-31 | 13G | Zura Bio Limited ZURA |
ADAR1 Capital Management, LLC | 2,077,251 3.180% |
-1,255,584 (-37.67%) |
Filing History |
| 2025-02-14 9:04 pm Purchase |
2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT |
ADAR1 Capital Management, LLC | 6,994,246 9.990% |
6,994,246 (New Position) |
Filing History |
| 2025-02-14 9:04 pm Sale |
2024-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ADAR1 Capital Management, LLC | 298,955 4.910% |
-181,476 (-37.77%) |
Filing History |
| 2024-11-14 4:49 pm Purchase |
2024-09-30 | 13G | Kala Pharmaceuticals, Inc. KALA |
ADAR1 Capital Management, LLC | 480,431 9.990% |
480,431 (New Position) |
Filing History |
| 2024-11-14 4:48 pm Purchase |
2024-09-30 | 13G | iBio, Inc. IBIO |
ADAR1 Capital Management, LLC | 966,298 9.990% |
966,298 (New Position) |
Filing History |
| 2024-11-14 4:47 pm Purchase |
2024-09-30 | 13G | Cellectar Biosciences, Inc. CLRB |
ADAR1 Capital Management, LLC | 3,684,708 8.510% |
3,684,708 (New Position) |
Filing History |
| 2024-11-14 4:47 pm Purchase |
2024-09-30 | 13G | Zura Bio Limited ZURA |
ADAR1 Capital Management, LLC | 3,332,835 5.100% |
3,332,835 (New Position) |
Filing History |
| 2024-11-14 4:46 pm Purchase |
2024-09-30 | 13G | Perceptive Capital Solutions Corp Class A Ordinary Shares PCSC |
ADAR1 Capital Management, LLC | 750,000 8.420% |
750,000 (New Position) |
Filing History |
| 2024-11-14 4:45 pm Purchase |
2024-09-30 | 13G | Kiora Pharmaceuticals, Inc. KPRX |
ADAR1 Capital Management, LLC | 315,103 9.990% |
315,103 (New Position) |
Filing History |
| 2024-11-14 4:40 pm Purchase |
2024-09-30 | 13G | Acasti Pharma Inc. ACST |
ADAR1 Capital Management, LLC | 1,029,997 9.990% |
70,426 (+7.34%) |
Filing History |
| 2024-08-01 08:00 am Purchase |
2024-07-24 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
ADAR1 Capital Management, LLC | 138,641 10.500% |
138,641 (New Position) |
Filing History |
| 2024-07-10 9:10 pm Purchase |
2024-06-28 | 13G | Acasti Pharma Inc. ACST |
ADAR1 Capital Management, LLC | 959,571 10.200% |
959,571 (New Position) |
Filing History |